Koelina Ganguly1, Jesse L Cox2, Dario Ghersi3, Paul M Grandgenett4, Michael A Hollingsworth4, Maneesh Jain5, Sushil Kumar1, Surinder K Batra6. 1. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska. 2. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska. 3. School of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, Nebraska. 4. Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska. 5. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska; Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska. 6. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska; Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: sbatra@unmc.edu.
Abstract
BACKGROUND & AIMS: Secreted mucin 5AC (MUC5AC) promotes pancreatic cancer (PC) progression and chemoresistance, suggesting its clinical association with poor prognosis. RNA sequencing analysis from the autochthonous pancreatic tumors showed a significant stromal alteration on genetic ablation of Muc5ac. Previously, depletion or targeting the stromal fibroblasts showed an ambiguous effect on PC pathogenesis. Hence, identifying the molecular players and mechanisms driving fibroblast heterogeneity is critical for improved clinical outcomes. METHODS: Autochthonous murine models of PC (KrasG12D, Pdx1-Cre [KC] and KrasG12D, Pdx1-Cre, Muc5ac-/- [KCM]) and co-implanted allografts of murine PC cell lines (Muc5ac wild-type and CRISPR/Cas knockout) with adipose-derived mesenchymal stem cells (AD-MSCs) were used to assess the role of Muc5ac in stromal heterogeneity. Proliferation, migration, and surface expression of cell-adhesion markers on AD-MSCs were measured using live-cell imaging and flow cytometry. MUC5AC-interactome was investigated using mass-spectrometry and enzyme-linked immunosorbent assay. RESULTS: The KCM tumors showed a significant decrease in the expression of α-smooth muscle actin and fibronectin compared with histology-matched KC tumors. Our study showed that MUC5AC, carrying tumor secretome, gets enriched in the adipose tissues of tumor-bearing mice and patients with PC, promoting CD44/CD29 (integrin-β1) clustering that leads to Rac1 activation and migration of AD-MSCs. Furthermore, treatment with KC-derived serum enhanced proliferation and migration of AD-MSCs, which was abolished on Muc5ac-depletion or pharmacologic inhibition of CXCR2 and Rac1, respectively. The AD-MSCs significantly contribute toward α-smooth muscle actin-positive cancer-associated fibroblasts population in Muc5ac-dependent manner, as suggested by autochthonous tumors, co-implantation xenografts, and patient tumors. CONCLUSION: MUC5AC, secreted during PC progression, enriches in adipose and enhances the mobilization of AD-MSCs. On recruitment to pancreatic tumors, AD-MSCs proliferate and contribute towards stromal heterogeneity.
BACKGROUND & AIMS: Secreted mucin 5AC (MUC5AC) promotes pancreatic cancer (PC) progression and chemoresistance, suggesting its clinical association with poor prognosis. RNA sequencing analysis from the autochthonous pancreatic tumors showed a significant stromal alteration on genetic ablation of Muc5ac. Previously, depletion or targeting the stromal fibroblasts showed an ambiguous effect on PC pathogenesis. Hence, identifying the molecular players and mechanisms driving fibroblast heterogeneity is critical for improved clinical outcomes. METHODS: Autochthonous murine models of PC (KrasG12D, Pdx1-Cre [KC] and KrasG12D, Pdx1-Cre, Muc5ac-/- [KCM]) and co-implanted allografts of murine PC cell lines (Muc5ac wild-type and CRISPR/Cas knockout) with adipose-derived mesenchymal stem cells (AD-MSCs) were used to assess the role of Muc5ac in stromal heterogeneity. Proliferation, migration, and surface expression of cell-adhesion markers on AD-MSCs were measured using live-cell imaging and flow cytometry. MUC5AC-interactome was investigated using mass-spectrometry and enzyme-linked immunosorbent assay. RESULTS: The KCM tumors showed a significant decrease in the expression of α-smooth muscle actin and fibronectin compared with histology-matched KC tumors. Our study showed that MUC5AC, carrying tumor secretome, gets enriched in the adipose tissues of tumor-bearing mice and patients with PC, promoting CD44/CD29 (integrin-β1) clustering that leads to Rac1 activation and migration of AD-MSCs. Furthermore, treatment with KC-derived serum enhanced proliferation and migration of AD-MSCs, which was abolished on Muc5ac-depletion or pharmacologic inhibition of CXCR2 and Rac1, respectively. The AD-MSCs significantly contribute toward α-smooth muscle actin-positive cancer-associated fibroblasts population in Muc5ac-dependent manner, as suggested by autochthonous tumors, co-implantation xenografts, and patient tumors. CONCLUSION: MUC5AC, secreted during PC progression, enriches in adipose and enhances the mobilization of AD-MSCs. On recruitment to pancreatic tumors, AD-MSCs proliferate and contribute towards stromal heterogeneity.
Authors: Berna C Özdemir; Tsvetelina Pentcheva-Hoang; Julienne L Carstens; Xiaofeng Zheng; Chia-Chin Wu; Tyler R Simpson; Hanane Laklai; Hikaru Sugimoto; Christoph Kahlert; Sergey V Novitskiy; Ana De Jesus-Acosta; Padmanee Sharma; Pedram Heidari; Umar Mahmood; Lynda Chin; Harold L Moses; Valerie M Weaver; Anirban Maitra; James P Allison; Valerie S LeBleu; Raghu Kalluri Journal: Cancer Cell Date: 2014-05-22 Impact factor: 31.743
Authors: Joao Incio; Hao Liu; Priya Suboj; Shan M Chin; Ivy X Chen; Matthias Pinter; Mei R Ng; Hadi T Nia; Jelena Grahovac; Shannon Kao; Suboj Babykutty; Yuhui Huang; Keehoon Jung; Nuh N Rahbari; Xiaoxing Han; Vikash P Chauhan; John D Martin; Julia Kahn; Peigen Huang; Vikram Desphande; James Michaelson; Theodoros P Michelakos; Cristina R Ferrone; Raquel Soares; Yves Boucher; Dai Fukumura; Rakesh K Jain Journal: Cancer Discov Date: 2016-05-31 Impact factor: 39.397
Authors: Albrecht Neesse; Christian Alexander Bauer; Daniel Öhlund; Matthias Lauth; Malte Buchholz; Patrick Michl; David A Tuveson; Thomas M Gress Journal: Gut Date: 2018-09-03 Impact factor: 23.059
Authors: Ainhoa Arina; Christian Idel; Elizabeth M Hyjek; Maria-Luisa Alegre; Ying Wang; Vytautas P Bindokas; Ralph R Weichselbaum; Hans Schreiber Journal: Proc Natl Acad Sci U S A Date: 2016-06-17 Impact factor: 11.205
Authors: Daniel Öhlund; Abram Handly-Santana; Giulia Biffi; Ela Elyada; Ana S Almeida; Mariano Ponz-Sarvise; Vincenzo Corbo; Tobiloba E Oni; Stephen A Hearn; Eun Jung Lee; Iok In Christine Chio; Chang-Il Hwang; Hervé Tiriac; Lindsey A Baker; Dannielle D Engle; Christine Feig; Anne Kultti; Mikala Egeblad; Douglas T Fearon; James M Crawford; Hans Clevers; Youngkyu Park; David A Tuveson Journal: J Exp Med Date: 2017-02-23 Impact factor: 14.307